Pharsight

1. Epinephrine patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9283197	April, 2019	Terminated-Settled	Belcher Pharmaceuticals, LLC	Adamis Pharmaceuticals Corporation

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039728	BELCHER	More potent and less toxic formulations of epinephrine and methods of medical use	Aug, 2034 (10 years from now)
US10004700	BELCHER	More potent and less toxic formulations of epinephrine and methods of medical use	Aug, 2034 (10 years from now)
US9283197	BELCHER	More potent and less toxic formulations of epinephrine and methods of medical use	Aug, 2034 (10 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 29 July, 2014

Treatment: Increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock; Emergency treatment of allergic reactions (type 1), including anaphylaxis; A method of treating...

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS; SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg/mL	13 Aug, 2020	1		15 Aug, 2034

Strength	Dosage	Availability
10MG/10ML (1MG/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	Prescription
1MG/ML (1MG/ML)	SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS	Prescription